Ensartinib is a drug indicated for the treatment of certain subtypes of lung adenocarcinoma, especially the ALK-positive subtype of non-small cell lung cancer. Its efficacy and associated survival duration vary from person to person, but the key data can be summarized as follows:
1.Clinical trial data show that ensartinib can significantly prolong progression-free survival (PFS). In one study, the median progression-free survival reached approximately 25.8 months.
2.Overall survival (OS) is also affected by multiple factors, such as the patient’s physical condition, specific tumor characteristics and response to the drug. Ensartinib helps extend overall survival time, yet the specific duration in months may differ from individual to individual.
3.Different patients may have varying responses and tolerability to ensartinib, so regular examinations and follow-ups are extremely crucial.
Ensartinib has the potential to improve the survival duration of patients with advanced and metastatic lung adenocarcinoma, but its specific efficacy must be determined based on the individual's condition and the evaluation of professional physicians.
